Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
psilocybin
Biotech
Compass guides psychedelic to 2nd pivotal depression win
The phase 3 win in treatment-resistant depression sent the biotech’s share price up 30% and teed up talks about filing for approval.
Nick Paul Taylor
Feb 17, 2026 8:39am
Fierce Pharma
Cybin alters state to become Helus Pharma for Nasdaq trip
Dec 19, 2025 10:30am
Reunion's psychedelic reduces postpartum depression in ph. 2
Aug 18, 2025 7:52am
Compass' psychedelic therapy wins ph. 3, investors unimpressed
Jun 23, 2025 8:05am
Psyence walks away from acquisition of fellow psilocybin biotech
Oct 7, 2024 5:16am
Psyence acquires fellow psilocybin biotech Clairvoyant
Sep 6, 2024 9:25am
